|Determination of Factor II Codons Genotype in Southeastern Iranian Patients With Hereditary Deficiency of Factor II|
|Hamed Soleimani Samarkhazan1, Shaban Alizadeh1, Ziba Majidi2, Zahra Kashani Khatib3, Majid Naderi4|
|1Department of Hematology and Transfusion Medicine, School of Allied Medicine, Tehran University of Medical Sciences, Tehran, Iran
2Department of Medical Laboratory Science, School of Allied Medicine, Tehran University of Medical Sciences, Tehran, Iran
3Laboratory Hematology and Blood Banking, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran
4Department of Hematology and Transfusion Medicine, School of Allied Medicine, Zahedan University of Medical Sciences, Zahedan, Iran
CJMB 2023; 10: 061-066
Viewed : 334 times
Downloaded : 336 times.
Keywords : Factor II deficiency, Prothrombin, Congenital bleeding disorders, Blood coagulation factor
|Full Text(PDF) | Related Articles|
Objectives: Congenital prothrombin (factor II) deficiency is an inherited rare bleeding disorder with an autosomal recessive manner. The prevalence of this disorder is about one in 2 000 000 people in general population, but it is more common in areas with a high rate of consanguinity. To date, there is no report on the absence of prothrombin, which is a life-threating disorder. Considering the importance of factor II in body homeostasis, this study aimed to find any possible mutation of coagulation factor II codons in patients with inherited factor II deficiency in southeastern Iran.
Materials and Methods: This study was conducted on 12 patients with inherited deficiency of prothrombin. Early diagnosis was based on clinical symptoms, laboratory evaluation, and family history. Then, the function level of prothrombin was measured, the initial diagnosis of disease was confirmed, and polymerase chain reaction (PCR) analysis was performed. Finally, gene sequencing and genotyping of factor II was done.
Results: Molecular analysis indicated a point mutation in exon 7 in three patients and a frameshift mutation in exon 14 due to addition of a thymine base at position 1760-1761 in one patient, both of which have been reported for the first time.
Conclusions: Molecular methods performed on patients from Southeastern Iranian population in terms of coagulation factor II deficiency revealed a substitution mutation in exon 7 in three patients and a frameshift mutation in exon 14 in one patient, both of which were reported for the first time. Considering the significant difference between the clinical symptoms of the present study and previous studies, probably the type of mutations reported in this study (for the first time) caused these clinical symptoms, but statistical studies did not show any relationship between the type of mutation and the occurrence of clinical symptoms. And it needs more investigations on more patients, with a larger population.
Cite By, Google Scholar